- Net loss widened to $81.7M ($0.37/share) in Q3 from $74.1M ($0.43/share) in Q3 2025
- Revenue remained negligible, operating expenses increased to $90.2M
- Cash, equivalents and investments stood at $848.6M as of September 30
Signal #134628 · SEC 8-K
$RLAY SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $RLAY filing catalyst
Why did $RLAY trigger an AI stock catalyst alert?
$RLAY triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: Relay Therapeutics Reports Q3 Net Loss of $81.7M and Pipeline Updates. Key points: - Net loss widened to $81.7M ($0.37/share) in Q3 from $74.1M ($0.43/share) in Q3 2025 - Revenue remained negligible, operating expenses increased to $90.2M - Cash, equivalents and investments stood at $848.6M as of September 30
How did $RLAY stock react after the SEC filing?
After the SEC 8-K for $RLAY, observed market reaction: T0 price $18.03. Past moves do not guarantee future results.
Where can I get real-time $RLAY SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $RLAY via Telegram and the VIP Web Terminal from €10/month.